- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 149468, 10 pages
Efficacy and Safety of Medicinal Plants or Related Natural Products for Fibromyalgia: A Systematic Review
1Department of Physiology, Federal University of Sergipe, Marechal Rondom Avenue, 49000-100 São Cristovão, SE, Brazil
2Collegiate of Physical Therapy, Federal University of Sergipe, Cláudio Batista Street, 49060-100 Aracaju, SE, Brazil
3Department of Nursing and Pharmacy, Federal University of Alagoas, Lourival de Mello Motta Avenue, 57072-970 Maceió, AL, Brazil
4Department of Pharmaceutical Sciences, Federal University of São Francisco Valley, José de Sá Maniçoba Avenue, 56304205 Petrolina, PE, Brazil
5Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Octávio Pinheiro Brisola Street, 17012-901 Bauru, SP, Brazil
Received 1 April 2013; Accepted 14 May 2013
Academic Editor: Cayetano Alegre
Copyright © 2013 Simone de Souza Nascimento et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. R. Pillemer, L. A. Bradley, L. J. Crofford, H. Moldofsky, and G. P. Chrousos, “The neuroscience and endocrinology of fibromyalgia,” Arthritis and Rheumatism, vol. 40, no. 11, pp. 1928–1939, 1997.
- R. Staud, C. J. Vierck, R. L. Cannon, A. P. Mauderli, and D. D. Price, “Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome,” Pain, vol. 91, no. 1-2, pp. 165–175, 2001.
- R. Staud, C. J. Vierck, M. E. Robinson, and D. D. Price, “Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects,” Journal of Pain, vol. 6, no. 5, pp. 323–332, 2005.
- L. A. Nielsen and K. G. Henriksson, “Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition,” Best Practice and Research: Clinical Rheumatology, vol. 21, no. 3, pp. 465–480, 2007.
- D. Dadabhoy, L. J. Crofford, M. Spaeth, I. J. Russell, and D. J. Clauw, “Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome,” Arthritis Research and Therapy, vol. 10, no. 4, article 211, 2008.
- R. A. Dionne, “Pharmacologic treatments for temporomandibular disorders,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 83, no. 1, pp. 134–142, 1997.
- D. Xu, V. Trajkovic, D. Hunter, et al., “IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background,” European Journal of Immunology, vol. 30, no. 11, pp. 3147–3156, 2000.
- D. J. Clauw, L. M. Arnold, and B. H. McCarberg, “The science of fibromyalgia,” Mayo Clinic Proceedings, vol. 86, no. 9, pp. 907–911, 2011.
- K. Srinivasan, S. Muruganandan, J. Lal, S. Chandra, S. K. Tandan, and V. Ravi Prakash, “Evaluation of anti-inflammatory activity of Pongamia pinnata leaves in rats,” Journal of Ethnopharmacology, vol. 78, no. 2-3, pp. 151–157, 2001.
- A. M. Venâncio, M. Marchioro, C. S. Estavam et al., “Ocimum basilicum leaf essential oil and (-)-linalool reduce orofacial nociception in rodents: a behavioral and electrophysiological approach,” Revista Brasileira de Farmacognosia, vol. 21, no. 6, pp. 1043–1051, 2011.
- D. Butler, “Translational research: crossing the valley of death,” Nature, vol. 453, no. 7197, pp. 840–842, 2008.
- S. C. H. Vieira, S. Sólon, M. C. Vieira, and N. A. Heredia Zárate, “Levantamento de fitoterápicos manipulados em farmácias magistrais de Dourados-MS,” Revista Brasileira de Farmacognosia, vol. 20, no. 1, pp. 28–34, 2010.
- J. B. Calixto, A. Beirith, J. Ferreira, A. R. Santos, V. C. Filho, and R. A. Yunes, “Naturally occurring antinociceptive substances from plants,” Phytotherapy Research, vol. 14, no. 6, pp. 401–418, 2000.
- J. Wang and X. Xiong, “Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 697237, 7 pages, 2012.
- B. Casanueva, B. Rodero, C. Quintial, J. Llorca, and M. A. González-Gay, “Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients,” Rheumatology International, 2012.
- G. D. Ko, A. Hum, G. Traitses, and D. Berbrayer, “Effects of topical O24 essential oils on patients with fibromyalgia syndrome: a randomized, placebo controlled pilot study,” Journal of Musculoskeletal Pain, vol. 15, no. 1, pp. 11–19, 2007.
- R. E. Lister, “An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome,” Journal of International Medical Research, vol. 30, no. 2, pp. 195–199, 2002.
- D. Lukaczer, G. Darland, M. Tripp, et al., “A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia,” Phytotherapy Research, vol. 19, no. 10, pp. 864–869, 2005.
- D. J. McCarty, M. Csuka, G. McCarthy, and D. Trotter, “Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study,” Seminars in Arthritis and Rheumatism, vol. 23, supplement 3, pp. 41–47, 1994.
- D. N. Rutledge and C. J. Jones, “Effects of topical essential oil on exercise volume after a 12-week exercise program for women with fibromyalgia: a pilot study,” Journal of Alternative and Complementary Medicine, vol. 13, no. 10, pp. 1099–1106, 2007.
- R. Q. Skrabek, L. Galimova, K. Ethans, and D. Perry, “Nabilone for the treatment of pain in fibromyalgia,” Journal of Pain, vol. 9, no. 2, pp. 164–173, 2008.
- M. A. Ware, M. Fitzcharles, L. Joseph, and Y. Shir, “The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial,” Anesthesia and Analgesia, vol. 110, no. 2, pp. 604–610, 2010.
- A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996.
- J. J. Shuster, “Review: cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors,” Research Synthesis Methods, vol. 2, no. 2, pp. 126–130, 2011.
- F. Wolfe, D. J. Clauw, M. Fitzcharles et al., “The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity,” Arthritis Care and Research, vol. 62, no. 5, pp. 600–610, 2010.
- Y. Chong and B. Ng, “Clinical aspects and management of fibromyalgia syndrome,” Annals of the Academy of Medicine Singapore, vol. 38, no. 11, pp. 967–973, 2009.
- D. Buskila, “Developments in the scientific and clinical understanding of fibromyalgia,” Arthritis Research and Therapy, vol. 11, no. 5, article 242, 2009.
- S. Silverman, A. Sadosky, C. Evans, Y. Yeh, J. M. J. Alvir, and G. Zlateva, “Toward characterization and definition of fibromyalgia severity,” BMC Musculoskeletal Disorders, vol. 11, no. 1, article 66, 2010.
- M. A. Fitzcharles, P. A. Ste-Marie, D. L. Goldenberg, et al., “2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome”.
- R. S. Katz, F. Wolfe, and K. Michaud, “Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 169–176, 2006.
- M. J. Caterina, M. A. Schumacher, M. Tominaga, T. A. Rosen, J. D. Levine, and D. Julius, “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature, vol. 389, no. 6653, pp. 816–824, 1997.
- C. Noto, M. Pappagallo, and A. Szallasi, “NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain,” Current Opinion in Investigational Drugs, vol. 10, no. 7, pp. 702–710, 2009.
- A. Szallasi, “Autoradiographic visualization and pharmacological characterization of vanilloid (capsaicin) receptors in several species, including man,” Acta Physiologica Scandinavica, Supplement, vol. 155, no. 629, pp. 1–68, 1995.
- A. Szallasi and P. M. Blumberg, “Vanilloid (Capsaicin) receptors and mechanisms,” Pharmacological Reviews, vol. 51, no. 2, pp. 159–211, 1999.
- M. Nolano, D. A. Simone, G. Wendelschafer-Crabb, T. Johnson, E. Hazen, and W. R. Kennedy, “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation,” Pain, vol. 81, no. 1-2, pp. 135–145, 1999.
- E. Palazzo, F. Rossi, and S. Maione, “Role of TRPV1 receptors in descending modulation of pain,” Molecular and Cellular Endocrinology, vol. 286, no. 1-2, pp. S79–S83, 2008.
- S. Maione, T. Bisogno, V. de Novellis et al., “Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 3, pp. 969–982, 2006.
- Y. Jia, R. L. McLeod, and J. A. Hey, “TRPV1 receptor: a target for the treatment of pain, cough, airway disease and urinary incontinence,” Drug News and Perspectives, vol. 18, no. 3, pp. 165–171, 2005.
- S. M. Bigatti, A. M. Hernandez, T. A. Cronan, and K. L. Rand, “Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression,” Arthritis Care and Research, vol. 59, no. 7, pp. 961–967, 2008.
- S. M. Harding, “Sleep in fibromyalgia patients: subjective and objective findings,” The American Journal of the Medical Sciences, vol. 315, no. 6, pp. 367–376, 1998.
- E. B. Russo, “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1344–1364, 2011.
- E. B. Russo, “Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?” Neuroendocrinology Letters, vol. 25, no. 1-2, pp. 31–39, 2004.
- B. F. Cravatt and A. H. Lichtman, “The endogenous cannabinoid system and its role in nociceptive behavior,” Journal of Neurobiology, vol. 61, no. 1, pp. 149–160, 2004.
- G. Pugh Jr., D. J. Mason Jr., V. Combs, and S. P. Welch, “Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord,” Journal of Pharmacology and Experimental Therapeutics, vol. 281, no. 2, pp. 730–737, 1997.
- E. M. Sanchez Robles, A. Bagues Arias, and M. I. Martin Fontelles, “Cannabinoids and muscular pain. Effectiveness of the local administration in rat,” European Journal of Pain, vol. 16, no. 8, pp. 1116–1127, 2012.
- G. Traitses, A. Hum, G. Ko, et al., “435 topical essential oils for fibromyalgia neuropathic pain: a randomized controlled trial,” European Journal of Pain, vol. 11, supplement 1, pp. S192–S193, 2007.
- M. Cohen, R. Wolfe, T. Mai, and D. Lewis, “A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee,” Journal of Rheumatology, vol. 30, no. 3, pp. 523–528, 2003.
- H. Gobel, G. Schmidt, and D. Soyka, “Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters,” Cephalalgia, vol. 14, no. 3, pp. 228–234, 1994.
- R. H. Davis, K. Y. Rosenthal, L. R. Cesario, and G. A. Rouw, “Processed Aloe vera administered topically inhibits inflammation,” Journal of the American Podiatric Medical Association, vol. 79, no. 8, pp. 395–397, 1989.
- C. Hong and F. G. Shellock, “Effects of a topically applied counterirritant (Eucalyptamint) on cutaneous blood flow and on skin and muscle temperatures. A placebo-controlled study,” American Journal of Physical Medicine and Rehabilitation, vol. 70, no. 1, pp. 29–33, 1991.
- D. da Costa, M. Abrahamowicz, I. Lowensteyn et al., “A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia,” Rheumatology, vol. 44, no. 11, pp. 1422–1427, 2005.
- L. Bressan, L. Matsutani, A. Assumpção, et al., “Efeitos do alongamento muscular e condicionamento físico no tratamento fisioterápico de pacientes com fibromialgia,” Revista Brasileira de Fisioterapia, vol. 12, pp. 88–93, 2008.
- K. D. Jones, D. Adams, K. Winters-Stone, and C. S. Burckhardt, “A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988–2005),” Health and Quality of Life Outcomes, vol. 4, no. 1, article 67, 2006.
- R. Çeliker and P. Borman, “Fibromyalgia versus rheumatoid arthritis: a comparison of psychological disturbance and life satisfaction,” Journal of Musculoskeletal Pain, vol. 9, no. 1, pp. 35–45, 2001.
- J. I. Hudson and H. G. Pope Jr., “The relationship between fibromyalgia and major depressive disorder,” Rheumatic Disease Clinics of North America, vol. 22, no. 2, pp. 285–303, 1996.
- C. Pae, P. Luyten, D. M. Marks et al., “The relationship between fibromyalgia and major depressive disorder: a comprehensive review,” Current Medical Research and Opinion, vol. 24, no. 8, pp. 2359–2371, 2008.
- D. G. Machado, L. E. B. Bettio, M. P. Cunha et al., “Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 4, pp. 642–650, 2009.
- L. Jie, “Pharmacology of oleanolic acid and ursolic acid,” Journal of Ethnopharmacology, vol. 49, no. 2-1, pp. 57–68, 1995.
- J. L. Maia, R. C. P. Lima-Júnior, C. M. Melo et al., “Oleanolic acid, a pentacyclic triterpene attenuates capsaicin-induced nociception in mice: possible mechanisms,” Pharmacological Research, vol. 54, no. 4, pp. 282–286, 2006.
- H. S. J. Picavet and N. Hoeymans, “Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study,” Annals of the Rheumatic Diseases, vol. 63, no. 6, pp. 723–729, 2004.
- A. P. Marques, A. M. Barsante Santos, A. Assumpção, L. A. Matsutani, L. V. Lage, and C. A. B. Pereira, “Validation of the Brazilian version of the Fibromyalgia Impact Questionnaire (FIQ),” Revista Brasileira de Reumatologia, vol. 46, no. 1, pp. 24–31, 2006.
- S. Bagis, L. Tamer, G. Sahin et al., “Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder?” Rheumatology International, vol. 25, no. 3, pp. 188–190, 2005.
- G. Berti, C. Schallenberger, L. Haas, et al., “Hidroterapia aplicada ao tratamento da fibromialgia: avaliação clínica e laboratorial de pacientes atendidos no Centro Universitário Feevale,” Novo Hamburgo (RS), 2008.
- S. Ozgocmen, H. Ozyurt, S. Sogut, and O. Akyol, “Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide,” Rheumatology International, vol. 26, no. 7, pp. 585–597, 2006.
- P. Zeppilli, B. Merlino, A. de Luca, et al., “Influence of coenzyme Q10 on physical work capacity in athletes, sedentary people and patients with mitochondrial disease,” in Blomedical and Clinical Aspects of Coenzyme Q10, vol. 6, 1991.
- J. Kleijnen and P. Knipschild, “Ginkgo biloba,” The Lancet, vol. 340, no. 8828, pp. 1136–1139, 1992.
- F. Firenzuoli and L. Gori, “Herbal medicine today: clinical and research issues,” Evidence-Based Complementary and Alternative Medicine, vol. 4, supplement 1, pp. 37–40, 2007.